<?xml version='1.0' encoding='UTF-8'?>
<extracted-tables-set><pmcid>6603131</pmcid><all-ids><article-id xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" pub-id-type="pmid">31293411</article-id><article-id xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" pub-id-type="pmc">6603131</article-id><article-id xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" pub-id-type="doi">10.3389/fnagi.2019.00139</article-id></all-ids><extracted-table><table-id>T1</table-id><table-label>Table 1</table-label><table-caption>Demographic characteristics and clinical assessments.</table-caption><original-table><table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="T1" position="float"><label>Table 1</label><caption><p>Demographic characteristics and clinical assessments.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">NC (<italic>n</italic> = 35)</th><th align="center" rowspan="1" colspan="1">PD (<italic>n</italic> = 35)</th><th align="center" rowspan="1" colspan="1">Statistical <italic>p</italic>-value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age (years)</td><td align="center" rowspan="1" colspan="1">60 ± 6</td><td align="center" rowspan="1" colspan="1">63 ± 12</td><td align="center" rowspan="1" colspan="1">0.0989</td></tr><tr><td align="left" rowspan="1" colspan="1">Sex (female/male)</td><td align="center" rowspan="1" colspan="1">24/11</td><td align="center" rowspan="1" colspan="1">18/17</td><td align="center" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" rowspan="1" colspan="1">Education time</td><td align="center" rowspan="1" colspan="1">11.08 ± 2.84</td><td align="center" rowspan="1" colspan="1">9.43 ± 3.31</td><td align="center" rowspan="1" colspan="1">0.0277</td></tr><tr><td align="left" rowspan="1" colspan="1">(years)</td></tr><tr><td align="left" rowspan="1" colspan="1">Hand dominance</td><td align="center" rowspan="1" colspan="1">0/35</td><td align="center" rowspan="1" colspan="1">2/33</td><td align="center" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" rowspan="1" colspan="1">(left/right)</td></tr><tr><td align="left" rowspan="1" colspan="1">Disease duration</td><td align="center" rowspan="1" colspan="1">NA</td><td align="center" rowspan="1" colspan="1">4.19 ± 3.97</td><td align="center" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" rowspan="1" colspan="1">(years)</td></tr><tr><td align="left" rowspan="1" colspan="1">H&amp;Y scores</td><td align="center" rowspan="1" colspan="1">NA</td><td align="center" rowspan="1" colspan="1">2.44 ± 0.72</td><td align="center" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" rowspan="1" colspan="1">UPDRS-III scores</td><td align="center" rowspan="1" colspan="1">NA</td><td align="center" rowspan="1" colspan="1">31.93 ± 14.56</td><td align="center" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" rowspan="1" colspan="1">(medication-on)</td></tr><tr><td align="left" rowspan="1" colspan="1">FAB scores</td><td align="center" rowspan="1" colspan="1">17.17 ± 1.34</td><td align="center" rowspan="1" colspan="1">15.16 ± 2.44 (<italic>n</italic> = 31)</td><td align="center" rowspan="1" colspan="1">&lt;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">Levodopa equivalent</td><td align="center" rowspan="1" colspan="1">NA</td><td align="center" rowspan="1" colspan="1">431.95 ± 383.33</td><td align="center" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" rowspan="1" colspan="1">daily dose (mg)</td></tr><tr><td align="left" rowspan="1" colspan="1">Mean FD (mm)</td><td align="center" rowspan="1" colspan="1">0.088 ± 0.064</td><td align="center" rowspan="1" colspan="1">0.069 ± 0.031</td><td align="center" rowspan="1" colspan="1">0.1284</td></tr></tbody></table><table-wrap-foot><p><italic>NC, normal controls; PD, Parkinson’s disease; FD, framewise displacement of Jenkinson; H&amp;Y, Hoehn &amp; Yahr; UPDRS-III, Unified Parkinson’s Disease Rating Scale (part three); FAB, Frontal assessment battery; NA, not applicable. Data was noted as average ± standard deviation. Statistical <italic>p</italic>-value was obtained by two-sample <italic>t</italic>-test with significance level of <italic>p</italic> &lt; 0.05</italic>.</p></table-wrap-foot></table-wrap></original-table><transformed-table>Table 1<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Demographic characteristics and clinical assessments.</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><thead><tr><th/><th align="center">NC (n = 35)</th><th align="center">PD (n = 35)</th><th align="center">Statistical p-value</th></tr></thead><tbody><tr><td align="left">Age (years)</td><td align="center">60 ± 6</td><td align="center">63 ± 12</td><td align="center">0.0989</td></tr><tr><td align="left">Sex (female/male)</td><td align="center">24/11</td><td align="center">18/17</td><td align="center">NA</td></tr><tr><td align="left">Education time</td><td align="center">11.08 ± 2.84</td><td align="center">9.43 ± 3.31</td><td align="center">0.0277</td></tr><tr><td align="left">(years)</td></tr><tr><td align="left">Hand dominance</td><td align="center">0/35</td><td align="center">2/33</td><td align="center">NA</td></tr><tr><td align="left">(left/right)</td></tr><tr><td align="left">Disease duration</td><td align="center">NA</td><td align="center">4.19 ± 3.97</td><td align="center">NA</td></tr><tr><td align="left">(years)</td></tr><tr><td align="left">H&amp;Y scores</td><td align="center">NA</td><td align="center">2.44 ± 0.72</td><td align="center">NA</td></tr><tr><td align="left">UPDRS-III scores</td><td align="center">NA</td><td align="center">31.93 ± 14.56</td><td align="center">NA</td></tr><tr><td align="left">(medication-on)</td></tr><tr><td align="left">FAB scores</td><td align="center">17.17 ± 1.34</td><td align="center">15.16 ± 2.44 (n = 31)</td><td align="center">&lt;0.0001</td></tr><tr><td align="left">Levodopa equivalent</td><td align="center">NA</td><td align="center">431.95 ± 383.33</td><td align="center">NA</td></tr><tr><td align="left">daily dose (mg)</td></tr><tr><td align="left">Mean FD (mm)</td><td align="center">0.088 ± 0.064</td><td align="center">0.069 ± 0.031</td><td align="center">0.1284</td></tr></tbody></table></div>NC, normal controls; PD, Parkinson’s disease; FD, framewise displacement of Jenkinson; H&amp;Y, Hoehn &amp; Yahr; UPDRS-III, Unified Parkinson’s Disease Rating Scale (part three); FAB, Frontal assessment battery; NA, not applicable. Data was noted as average ± standard deviation. Statistical p-value was obtained by two-sample t-test with significance level of p &lt; 0.05.</transformed-table></extracted-table><extracted-table><table-id>T2</table-id><table-label>Table 2</table-label><table-caption>Brain regions showing significant degree centrality (DC) differences between normal controls (NC) and patients with Parkinson’s disease (PD).</table-caption><original-table><table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="T2" position="float"><label>Table 2</label><caption><p>Brain regions showing significant degree centrality (DC) differences between normal controls (NC) and patients with Parkinson’s disease (PD).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Side</th><th align="left" rowspan="1" colspan="1">Brain regions</th><th align="center" rowspan="1" colspan="1">Brodmann area</th><th align="center" rowspan="1" colspan="1">Cluster size (mm<sup>3</sup>)</th><th align="center" rowspan="1" colspan="1">Peak MNI coordinates (<italic>x y z</italic>)</th><th align="center" rowspan="1" colspan="1">Peak <italic>t</italic>-value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Left</td><td align="left" rowspan="1" colspan="1">Fusiform gyrus/Inferior temporal gyrus</td><td align="center" rowspan="1" colspan="1">20</td><td align="center" rowspan="1" colspan="1">1,890</td><td align="center" rowspan="1" colspan="1">−42 −15 −39</td><td align="center" rowspan="1" colspan="1">4.85</td></tr><tr><td align="left" rowspan="1" colspan="1">Left</td><td align="left" rowspan="1" colspan="1">Middle temporal gyrus/Angular gyrus</td><td align="center" rowspan="1" colspan="1">39</td><td align="center" rowspan="1" colspan="1">2,754</td><td align="center" rowspan="1" colspan="1">−60 −63 18</td><td align="center" rowspan="1" colspan="1">4.73</td></tr><tr><td align="left" rowspan="1" colspan="1">Right</td><td align="left" rowspan="1" colspan="1">Inferior opercular-frontal gyrus/Superior temporal gyrus</td><td align="center" rowspan="1" colspan="1">44/48</td><td align="center" rowspan="1" colspan="1">1,620</td><td align="center" rowspan="1" colspan="1">57 15 12</td><td align="center" rowspan="1" colspan="1">−4.59</td></tr></tbody></table><table-wrap-foot><p><italic>MNI, Montreal Neurological Institute. Positive/Negative statistical <italic>t</italic>-value indicated increased/decreased DC in PD</italic>.</p></table-wrap-foot></table-wrap></original-table><transformed-table>Table 2<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Brain regions showing significant degree centrality (DC) differences between normal controls (NC) and patients with Parkinson’s disease (PD).</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><thead><tr><th align="left">Side</th><th align="left">Brain regions</th><th align="center">Brodmann area</th><th align="center">Cluster size (mm3)</th><th align="center">Peak MNI coordinates (x y z)</th><th align="center">Peak t-value</th></tr></thead><tbody><tr><td align="left">Left</td><td align="left">Fusiform gyrus/Inferior temporal gyrus</td><td align="center">20</td><td align="center">1,890</td><td align="center">−42 −15 −39</td><td align="center">4.85</td></tr><tr><td align="left">Left</td><td align="left">Middle temporal gyrus/Angular gyrus</td><td align="center">39</td><td align="center">2,754</td><td align="center">−60 −63 18</td><td align="center">4.73</td></tr><tr><td align="left">Right</td><td align="left">Inferior opercular-frontal gyrus/Superior temporal gyrus</td><td align="center">44/48</td><td align="center">1,620</td><td align="center">57 15 12</td><td align="center">−4.59</td></tr></tbody></table></div>MNI, Montreal Neurological Institute. Positive/Negative statistical t-value indicated increased/decreased DC in PD.</transformed-table></extracted-table></extracted-tables-set>